what to expect week 1 semaglutide During the First of What to Expect with Semaglutide

In hypertensive rat models, chronic administration of quercetin, puerarin, or rutin leads to lowered blood pressure, associated with improved endothelial function and decreased oxidative stress markers (Zheng et al., 2024

MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) covered under standard Part D pathways

Food and Drug Administration cleared Ascletis Pharma to start a Phase 1 clinical trial of ASC35 , a once-monthly subcutaneous peptide that activates both the GLP-1 and GIP receptors

Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025

While typically mild and transient, injection site discomfort can impact treatment adherence and patient experience